Treatment | Parameter | |||
---|---|---|---|---|
TNF-α (pg/ml) | IL-4 (ng/ml) | |||
4Â weeks | 8Â weeks | 4Â weeks | 8Â weeks | |
Vehicle (CMC 1 %) control | 36.72 ± 1.02h | 38.72 ± 0.62h | 202 ± 4.37a | 197 ± 1.64a |
1/20 LD50 latex | 78.55 ± 6.28fg | 72.55 ± 7.10g | 130.7 ± 13.63c | 170.5 ± 15.17b |
1/10 LD50 latex | 91.43 ± 6.12def | 80.30 ± 5.74efg | 101.53 ± 3.99d | 112.9 ± 5.34cd |
1/20 LD50 ethanolic extract | 102.42 ± 6.53cd | 92.40 ± 3.67de | 179.3 ± 7.96ab | 186.97 ± 4.27ab |
1/10 LD50 ethanolic extract | 109.85 ± 4.29bc | 100.98 ± 3.52cd | 138 ± 11.67c | 181.4 ± 3.96ab |
1/20 LD50 abamectin | 100.67 ± 5.61cd | 86.62 ± 3.83ef | 184.9 ± 8.89ab | 199.27 ± 2.80a |
1/10 LD50 abamectin | 124 ± 3.08a | 117.95 ± 1.08ab | 134.97 ± 19.22c | 197.23 ± 1.95a |
F-probability | PÂ <Â 0.001 | Â | PÂ <Â 0.001 | Â |
LSD at 5Â % level | 13.4927 | Â | 26.4573 | Â |
LSD at 1Â % level | 18.1709 | Â | 35.6306 | Â |